General Information of Drug Therapeutic Target (DTT) (ID: TT2LBCR)

DTT Name HUMAN toll-like receptor 9 (TLR9)
Synonyms UNQ5798/PRO19605; TLR-9; CD289
Gene Name TLR9
BioChemical Class
Toll-like receptor
UniProt ID
TLR9_HUMAN
TTD ID
T87633
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MGFCRSALHPLSLLVQAIMLAMTLALGTLPAFLPCELQPHGLVNCNWLFLKSVPHFSMAA
PRGNVTSLSLSSNRIHHLHDSDFAHLPSLRHLNLKWNCPPVGLSPMHFPCHMTIEPSTFL
AVPTLEELNLSYNNIMTVPALPKSLISLSLSHTNILMLDSASLAGLHALRFLFMDGNCYY
KNPCRQALEVAPGALLGLGNLTHLSLKYNNLTVVPRNLPSSLEYLLLSYNRIVKLAPEDL
ANLTALRVLDVGGNCRRCDHAPNPCMECPRHFPQLHPDTFSHLSRLEGLVLKDSSLSWLN
ASWFRGLGNLRVLDLSENFLYKCITKTKAFQGLTQLRKLNLSFNYQKRVSFAHLSLAPSF
GSLVALKELDMHGIFFRSLDETTLRPLARLPMLQTLRLQMNFINQAQLGIFRAFPGLRYV
DLSDNRISGASELTATMGEADGGEKVWLQPGDLAPAPVDTPSSEDFRPNCSTLNFTLDLS
RNNLVTVQPEMFAQLSHLQCLRLSHNCISQAVNGSQFLPLTGLQVLDLSHNKLDLYHEHS
FTELPRLEALDLSYNSQPFGMQGVGHNFSFVAHLRTLRHLSLAHNNIHSQVSQQLCSTSL
RALDFSGNALGHMWAEGDLYLHFFQGLSGLIWLDLSQNRLHTLLPQTLRNLPKSLQVLRL
RDNYLAFFKWWSLHFLPKLEVLDLAGNQLKALTNGSLPAGTRLRRLDVSCNSISFVAPGF
FSKAKELRELNLSANALKTVDHSWFGPLASALQILDVSANPLHCACGAAFMDFLLEVQAA
VPGLPSRVKCGSPGQLQGLSIFAQDLRLCLDEALSWDCFALSLLAVALGLGVPMLHHLCG
WDLWYCFHLCLAWLPWRGRQSGRDEDALPYDAFVVFDKTQSAVADWVYNELRGQLEECRG
RWALRLCLEERDWLPGKTLFENLWASVYGSRKTLFVLAHTDRVSGLLRASFLLAQQRLLE
DRKDVVVLVILSPDGRRSRYVRLRQRLCRQSVLLWPHQPSGQRSFWAQLGMALTRDNHHF
YNRNFCQGPTAE
Function
Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Controls lymphocyte response to Helicobacter infection. Upon CpG stimulation, induces B-cell proliferation, activation, survival and antibody production.
KEGG Pathway
Toll-like receptor signaling pathway (hsa04620 )
Salmonella infection (hsa05132 )
Chagas disease (hsa05142 )
African trypanosomiasis (hsa05143 )
Malaria (hsa05144 )
Tuberculosis (hsa05152 )
Measles (hsa05162 )
Herpes simplex virus 1 infection (hsa05168 )
PD-L1 expression and PD-1 checkpoint pathway in cancer (hsa05235 )
Reactome Pathway
Trafficking and processing of endosomal TLR (R-HSA-1679131 )
Toll Like Receptor 9 (TLR9) Cascade (R-HSA-168138 )
Potential therapeutics for SARS (R-HSA-9679191 )
TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling (R-HSA-975110 )
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation (R-HSA-975138 )
MyD88 dependent cascade initiated on endosome (R-HSA-975155 )
PI3K Cascade (R-HSA-109704 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Drugs in Phase 2 Trial Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
PUL-042 DMW7L0Y Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 Trial [1]
------------------------------------------------------------------------------------

References

1 Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days.